23 February 2022
One of the studies, in which CZECRIN also participates to a large extent and is carried out by the National Institute of Mental Health (NÚDZ), is dedicated to the treatment of depression. In two studies (PSIKET001 and PSIKET002), NÚDZ deals with psychedelics as antidepressants and already provides valuable information about their effects. Psilocibyn has shown a rapid onset of action, which is also longer lasting compared to competing substances. You can listen to the presentation of the clinical research itself by the project leader in the ČT24 report (starts at 2:39:00; Presentation of the study design). For those who are more interested in the topic, we are also adding a few articles.